Status:
COMPLETED
Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia
Lead Sponsor:
Centenario Hospital Miguel Hidalgo
Conditions:
COVID-19 Pneumonia
Eligibility:
All Genders
16-90 years
Phase:
PHASE3
Brief Summary
Background: On December 2019, a new human coronavirus infection (COVID-19) was detected in China. Its infectivity and virulence characteristics caused a rapid spread, being declared pandemic on March ...
Detailed Description
I. Background: In late December 2019, the health authorities of the Popular Republic of China reported several cases of pneumonia of unknown origin in Wuhan City, Hubei Province, China. On December 3...
Eligibility Criteria
Inclusion
- Patients who are admitted to Hospital Centers with a positive RT-qPCR SARS-CoV-2 test or a CT scan compatible with a diagnosis of COVID-19 pneumonia, in addition to one of the following two criteria:
- Severe respiratory failure \[respiratory rate\> 25 - \<35 x minute, oxygen saturation ≤ 90% with reservoir mask (FiO2 = 100%)\]
- Requiring invasive mechanical ventilation.
Exclusion
- Patients with a viral infection other than COVID-19
Key Trial Info
Start Date :
May 6 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 26 2020
Estimated Enrollment :
196 Patients enrolled
Trial Details
Trial ID
NCT04381858
Start Date
May 6 2020
End Date
November 26 2020
Last Update
November 30 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centenario Hospital Miguel Hidalgo
Aguascalientes, Mexico, 20259